As 23andMe struggles, another genetic testing company bets on drug discovery

Two years ago, GeneDx was tee­ter­ing. The ge­net­ic test­ing com­pa­ny had laid off 33% of its staff, shares were down 90% from a year pri­or …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.